Liposomal imatinib–mitoxantrone combination: Formulation development and therapeutic evaluation in an animal model of prostate cancer
Log in with Open Athens, Shibboleth, or your institutional credentials.
If you have previously obtained access with your personal account, Please log in.
If you previously purchased this article, Log in to Readcube.
You previously purchased this article on READCUBE_PURCHASE_DATE. Click on an option below to access.
Logged in as READCUBE_USER. Log out of ReadCube.
Abstract
BACKGROUND
Mitoxantrone plus prednisone is a palliative treatment for hormone‐refractory prostate cancer (HRPC) but without survival benefit. Imatinib has shown activity against HRPC but only in the preclinical setting. Our previous in vitro cytotoxicity screening study established that their free combination act additively to inhibit proliferation of PC‐3 cells. We aim to develop a liposomal imatinib–mitoxantrone (LIM) formulation with improved in vivo therapeutic activity.
METHODS
Imatinib and mitoxantrone were simultaneously co‐loaded into DSPC/Chol liposomes by means of a (NH4)2SO4‐generated proton gradient method. The optimized formulation was characterized in terms of mean size diameter, loading parameters and drug retention in human serum. In vivo antitumor activity of developed LIM formulation was evaluated in a nude mice bearing subcutaneous PC‐3 xenograft model.
RESULTS
LIM formulation exhibited maximal encapsulation efficiency (>95%) and enhanced drug retention for both drugs. Additionally, this LIM formulation, administered at a low mitoxantrone dose (0.5 mg/kg), showed a tumor inhibition activity (TGI = 66.7% and 4.0‐fold tumor volume increase) slightly superior to that of liposomal mitoxantrone (LM) at 2 mg/kg (TGI = 53.0% and 4.2‐fold volume increase). Therefore, therapeutic activity of mitoxantrone was significantly improved by co‐loading with imatinib since a four times lower dose was needed to achieve an equivalent growth inhibition effect.
CONCLUSIONS
The loading parameters and drug retention properties of our LIM formulation, combined with its in vivo antitumor activity, make this formulation an excellent strategy to improve the therapeutic index of mitoxantrone and a promising candidate for clinical development in prostate cancer therapy. Prostate 71: 81–90, 2011. © 2010 Wiley‐Liss, Inc.
Number of times cited according to CrossRef: 19
- Shruti Rawal and Mayur M. Patel, Threatening cancer with nanoparticle aided combination oncotherapy, Journal of Controlled Release, 10.1016/j.jconrel.2019.03.015, 301, (76-109), (2019).
- Ahuva Cern, David Marcus, Alexander Tropsha, Yechezkel Barenholz and Amiram Goldblum, New drug candidates for liposomal delivery identified by computer modeling of liposomes' remote loading and leakage, Journal of Controlled Release, 10.1016/j.jconrel.2017.02.015, 252, (18-27), (2017).
- Mariana S. Oliveira, Livia P. Mendes and Vladmir P. Torchilin, Targeted delivery of anticancer drugs: new trends in lipid nanocarriers, Nanostructures for Cancer Therapy, 10.1016/B978-0-323-46144-3.00018-0, (455-484), (2017).
- Tingting Hu, Hua Cao, Chengli Yang, Lijing Zhang, Xiaohua Jiang, Xiang Gao, Fan Yang, Gu He, Xiangrong Song, Aiping Tong, Gang Guo, Changyang Gong, Rui Li, Xiaoning Zhang, Xinchun Wang and Yu Zheng, LHD-Modified Mechanism-Based Liposome Coencapsulation of Mitoxantrone and Prednisolone Using Novel Lipid Bilayer Fusion for Tissue-Specific Colocalization and Synergistic Antitumor Effects, ACS Applied Materials & Interfaces, 10.1021/acsami.5b10598, 8, 10, (6586-6601), (2016).
- Carolina Soekmadji and Colleen C. Nelson, The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer, BioMed Research International, 10.1155/2015/454837, 2015, (1-13), (2015).
- Lília R. Cordeiro Pedrosa, Timo L. M. ten Hagen, Regine Süss, Albert van Hell, Alexander M. M. Eggermont, Marcel Verheij and Gerben A. Koning, Short-Chain Glycoceramides Promote Intracellular Mitoxantrone Delivery from Novel Nanoliposomes into Breast Cancer Cells, Pharmaceutical Research, 10.1007/s11095-014-1539-4, 32, 4, (1354-1367), (2014).
- Jan Kroon, Josbert M. Metselaar, Gert Storm and Gabri van der Pluijm, Liposomal nanomedicines in the treatment of prostate cancer, Cancer Treatment Reviews, 10.1016/j.ctrv.2013.10.005, 40, 4, (578-584), (2014).
- Ala Qabaja, Tamer Jarada, Abdallah Elsheikh and Reda Alhajj, Prediction of gene-based drug indications using compendia of public gene expression data and PubMed abstracts, Journal of Bioinformatics and Computational Biology, 10.1142/S0219720014500073, 12, 03, (1450007), (2014).
- Nuno A. Fonseca, Ana C. Gregório, Ângela Valério-Fernandes, Sérgio Simões and João N. Moreira, Bridging cancer biology and the patients' needs with nanotechnology-based approaches, Cancer Treatment Reviews, 10.1016/j.ctrv.2014.02.002, 40, 5, (626-635), (2014).
- Chun-Chieh Liu, Jong-Ming Hsu, Li-Kuo Kuo and Chih-Pin Chuu, Caffeic acid phenethyl ester as an adjuvant therapy for advanced prostate cancer, Medical Hypotheses, 10.1016/j.mehy.2013.02.003, 80, 5, (617-619), (2013).
- Naama E. Toledano Furman, Yael Lupu-Haber, Tomer Bronshtein, Limor Kaneti, Nitzan Letko, Eyal Weinstein, Limor Baruch and Marcelle Machluf, Reconstructed Stem Cell Nanoghosts: A Natural Tumor Targeting Platform, Nano Letters, 10.1021/nl401376w, 13, 7, (3248-3255), (2013).
- Ahuva Cern, Alexander Golbraikh, Aleck Sedykh, Alexander Tropsha, Yechezkel Barenholz and Amiram Goldblum, Quantitative structure - property relationship modeling of remote liposome loading of drugs, Journal of Controlled Release, 10.1016/j.jconrel.2011.11.029, 160, 2, (147-157), (2012).
- Yoshie Maitani, Hiroshi Saito, Yuki Seishi, Yuko Iwase, Takayasu Yamauchi, Kimio Higashiyama and Takashi Sugino, A combination of liposomal sunitinib plus liposomal irinotecan and liposome co-loaded with two drugs enhanced antitumor activity in PC12-bearing mouse, Journal of Drug Targeting, 10.3109/1061186X.2012.723215, 20, 10, (873-882), (2012).
- Duen-Yi Huang, Yee Chao, Ming-Hui Tai, Yang-Hao Yu and Wan-Wan Lin, STI571 reduces TRAIL-induced apoptosis in colon cancer cells: c-Abl activation by the death receptor leads to stress kinase-dependent cell death, Journal of Biomedical Science, 10.1186/1423-0127-19-35, 19, 1, (35), (2012).
- Daniel Zucker, Alexander V. Andriyanov, Ariel Steiner, Uri Raviv and Yechezkel Barenholz, Characterization of PEGylated nanoliposomes co-remotely loaded with topotecan and vincristine: relating structure and pharmacokinetics to therapeutic efficacy, Journal of Controlled Release, 10.1016/j.jconrel.2011.10.003, 160, 2, (281-289), (2012).
- Hui-Ping Lin, Shih Sheng Jiang and Chih-Pin Chuu, Caffeic Acid Phenethyl Ester Causes p21Cip1 Induction, Akt Signaling Reduction, and Growth Inhibition in PC-3 Human Prostate Cancer Cells, PLoS ONE, 10.1371/journal.pone.0031286, 7, 2, (e31286), (2012).
- Hui-Ping Lin, Ching-Yu Lin, Chun-Chieh Liu, Liang-Cheng Su, Chieh Huo, Ying-Yu Kuo, Jen-Chih Tseng, Jong-Ming Hsu, Chi-Kuan Chen and Chih-Pin Chuu, Caffeic Acid Phenethyl Ester as a Potential Treatment for Advanced Prostate Cancer Targeting Akt Signaling, International Journal of Molecular Sciences, 10.3390/ijms14035264, 14, 3, (5264-5283), (2013).
- Hui-Ping Lin, Ching-Yu Lin, Ping-Hsuan Hsiao, Horng-Dar Wang, Shih Sheng Jiang, Jong-Ming Hsu, Wai-Tim Jim, Marcelo Chen, Hsing-Jien Kung and Chih-Pin Chuu, Difference in Protein Expression Profile and Chemotherapy Drugs Response of Different Progression Stages of LNCaP Sublines and Other Human Prostate Cancer Cells, PLoS ONE, 10.1371/journal.pone.0082625, 8, 12, (e82625), (2013).
- Kemal Alpay, Mehdi Farshchian, Johanna Tuomela, Jouko Sandholm, Kaappo Aittokallio, Elina Siljamäki, Marko Kallio, Veli-Matti Kähäri and Sakari Hietanen, Inhibition of c-Abl Kinase Activity Renders Cancer Cells Highly Sensitive to Mitoxantrone, PLoS ONE, 10.1371/journal.pone.0105526, 9, 8, (e105526), (2014).
